Crispr Therapeutics Ag (CRSP)

$55.52 -5.29 (-8.70%)
Market Cap 5.29B
Revenue (ttm) 37.31M
Net Income (ttm) -366.25M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -981.64%
Debt to Equity Ratio 0.00
Volume 2,393,000
Avg Vol 1,989,642
Day's Range N/A - N/A
Shares Out 95.30M
Stochastic %K 46%
Beta 1.70
Analysts Strong Sell
Price Target $82.62

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 41 561 32 77
Address:
Baarerstrasse 14, Zug, Switzerland
TopJaxon
TopJaxon Jan. 26 at 11:24 AM
Awesome call on BATL - Made me a sweet $17K profit🔥 Shout out to @ShortVenom he's been on fire. I recommend you Follow him. $SRPT $MNTS $KULR $CRSP Strap
0 · Reply
kirastock
kirastock Jan. 26 at 3:39 AM
$CRSP wonderful company
0 · Reply
svertical1
svertical1 Jan. 26 at 1:53 AM
$CRSP The Holy Grail of Genetic Engineering….Aging!
0 · Reply
abubnic
abubnic Jan. 25 at 11:32 PM
$CRSP stock was down by 8.7% on Friday, January 23, primarily due to the disclosure of an insider share sale by the CEO and general market rotation out of speculative growth stocks. The company started 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities, and expects 2026 to be a data- and milestone-rich year across the portfolio.
1 · Reply
skcots_13
skcots_13 Jan. 25 at 7:11 PM
$CRSP "Man, fucck Fontaine." "You don't fucck Fontaine. He fuccks you!".
0 · Reply
dachshund36
dachshund36 Jan. 25 at 6:35 PM
$CRSP I guess after the sale, insiders still hold enough shares to show confidence? What do you think?
0 · Reply
svertical1
svertical1 Jan. 25 at 5:11 AM
$CRSP $CADL IBRX up 200% since Jan 1st! $CADL & $CRSP Up Next!
0 · Reply
Information_Master
Information_Master Jan. 24 at 3:39 PM
PORTFOLIO UPDATE Natan YTD: +4.0% S&P500 YTD: +1.0% TOTAL RETURNS (Jan 2022) Natan's portfolio: +132.1% *Benchmark: +44.2% S&P500: +53.5% MY POSITIONS: 4.5% | B2gold $BTG 4.1% | Monday $MNDY 1.8% | Edwards Lifesciences $EW 1.2% | Crispr Therapeutics $CRSP END 👉Click to view @Information_Master for timely updates amid the volatility..
0 · Reply
handmedown1
handmedown1 Jan. 24 at 2:23 PM
$CRSP praying this is sold soon.
0 · Reply
handmedown1
handmedown1 Jan. 24 at 2:21 PM
$CRSP remember when they released the most exciting news in a sunday at like 3pm. Lmfao. What the fuck is this ponzi scheme i have invested in. Hopeful the BOD can get this sold soon to competent mgmt.
0 · Reply
Latest News on CRSP
Crispr Therapeutics: Patience And Opportunity Through Volatility

Jan 14, 2026, 11:30 AM EST - 11 days ago

Crispr Therapeutics: Patience And Opportunity Through Volatility

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:36 PM EST - 13 days ago

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 12, 2026, 8:36 AM EST - 13 days ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:30 AM EST - 20 days ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

Jan 2, 2026, 12:31 PM EST - 23 days ago

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Dec 31, 2025, 5:06 PM EST - 25 days ago

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

Dec 22, 2025, 12:45 PM EST - 4 weeks ago

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Dec 22, 2025, 8:30 AM EST - 4 weeks ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Dec 4, 2025, 10:29 AM EST - 7 weeks ago

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

Nov 13, 2025, 3:43 PM EST - 2 months ago

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 2 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 10:03 AM EST - 2 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Nov 8, 2025, 9:56 AM EST - 2 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 10, 2025, 8:00 AM EDT - 3 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Oct 1, 2025, 8:00 AM EDT - 4 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

Sep 17, 2025, 4:09 PM EDT - 4 months ago

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 4:00 PM EDT - 4 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

Sep 9, 2025, 2:22 PM EDT - 4 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 11:38 AM EDT - 4 months ago

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 6:53 AM EDT - 4 months ago

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

Sep 2, 2025, 8:55 AM EDT - 5 months ago

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 5 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Aug 27, 2025, 6:21 AM EDT - 5 months ago

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Aug 14, 2025, 1:02 PM EDT - 5 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

Aug 14, 2025, 7:27 AM EDT - 5 months ago

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 4:15 PM EDT - 6 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 23, 2025, 11:03 AM EDT - 6 months ago

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

The Big 3: ASML, GOOGL, CRSP

Jul 15, 2025, 12:01 PM EDT - 6 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

Jul 14, 2025, 8:00 AM EDT - 6 months ago

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 26, 2025, 7:00 AM EDT - 7 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

The Big 3: CRSP, OKLO, GME

Jun 23, 2025, 12:01 PM EDT - 7 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Crispr Therapeutics: Betting On A One-Shot Future

Jun 13, 2025, 6:27 PM EDT - 8 months ago

Crispr Therapeutics: Betting On A One-Shot Future

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 9, 2025, 5:50 PM EDT - 8 months ago

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Jun 3, 2025, 4:07 PM EDT - 8 months ago

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

May 9, 2025, 7:14 AM EDT - 9 months ago

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

May 8, 2025, 8:36 AM EDT - 9 months ago

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

May 7, 2025, 4:03 PM EDT - 9 months ago

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 2:17 PM EDT - 9 months ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 7, 2025, 8:39 AM EDT - 9 months ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 6, 2025, 4:01 PM EDT - 9 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 9 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

NTLA

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Apr 8, 2025, 3:29 PM EDT - 10 months ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 10 months ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 26, 2025, 4:01 PM EDT - 10 months ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

CRISPR Therapeutics Set To Reach Previous Heights

Mar 25, 2025, 11:03 AM EDT - 10 months ago

CRISPR Therapeutics Set To Reach Previous Heights

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

Mar 3, 2025, 3:28 PM EST - 11 months ago

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 11 months ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

Feb 13, 2025, 11:06 AM EST - 1 year ago

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 4:01 PM EST - 1 year ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

Feb 5, 2025, 4:16 PM EST - 1 year ago

CRISPR Therapeutics AG (CRSP) Guggenheim SMID Cap Biotech Conference (Transcript)

TopJaxon
TopJaxon Jan. 26 at 11:24 AM
Awesome call on BATL - Made me a sweet $17K profit🔥 Shout out to @ShortVenom he's been on fire. I recommend you Follow him. $SRPT $MNTS $KULR $CRSP Strap
0 · Reply
kirastock
kirastock Jan. 26 at 3:39 AM
$CRSP wonderful company
0 · Reply
svertical1
svertical1 Jan. 26 at 1:53 AM
$CRSP The Holy Grail of Genetic Engineering….Aging!
0 · Reply
abubnic
abubnic Jan. 25 at 11:32 PM
$CRSP stock was down by 8.7% on Friday, January 23, primarily due to the disclosure of an insider share sale by the CEO and general market rotation out of speculative growth stocks. The company started 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities, and expects 2026 to be a data- and milestone-rich year across the portfolio.
1 · Reply
skcots_13
skcots_13 Jan. 25 at 7:11 PM
$CRSP "Man, fucck Fontaine." "You don't fucck Fontaine. He fuccks you!".
0 · Reply
dachshund36
dachshund36 Jan. 25 at 6:35 PM
$CRSP I guess after the sale, insiders still hold enough shares to show confidence? What do you think?
0 · Reply
svertical1
svertical1 Jan. 25 at 5:11 AM
$CRSP $CADL IBRX up 200% since Jan 1st! $CADL & $CRSP Up Next!
0 · Reply
Information_Master
Information_Master Jan. 24 at 3:39 PM
PORTFOLIO UPDATE Natan YTD: +4.0% S&P500 YTD: +1.0% TOTAL RETURNS (Jan 2022) Natan's portfolio: +132.1% *Benchmark: +44.2% S&P500: +53.5% MY POSITIONS: 4.5% | B2gold $BTG 4.1% | Monday $MNDY 1.8% | Edwards Lifesciences $EW 1.2% | Crispr Therapeutics $CRSP END 👉Click to view @Information_Master for timely updates amid the volatility..
0 · Reply
handmedown1
handmedown1 Jan. 24 at 2:23 PM
$CRSP praying this is sold soon.
0 · Reply
handmedown1
handmedown1 Jan. 24 at 2:21 PM
$CRSP remember when they released the most exciting news in a sunday at like 3pm. Lmfao. What the fuck is this ponzi scheme i have invested in. Hopeful the BOD can get this sold soon to competent mgmt.
0 · Reply
Sdwg
Sdwg Jan. 23 at 11:14 PM
$CRSP ah, the dreaded short squeeze....this is just another stock under full control by illegal shorting....only a buyout will break them...
0 · Reply
handmedown1
handmedown1 Jan. 23 at 9:19 PM
$CRSP so fishy ceo sold at 60 yesterday... how did it get bid up so nice for him? Only to tank today. Disgusting and disappointed
2 · Reply
B00ger
B00ger Jan. 23 at 8:39 PM
$CRSP what is up with these wild swings in all the gene stocks?
1 · Reply
Ntlacrsp
Ntlacrsp Jan. 23 at 8:32 PM
$CRSP here ya go… As of January 23, 2026, CRISPR Therapeutics (CRSP) shares are experiencing a sharp decline following news of significant insider selling, with the stock trading down 5.8% to around $57.28 during mid-day trading.
0 · Reply
handmedown1
handmedown1 Jan. 23 at 8:18 PM
$CRSP mgmt is worthless. I hope the bod does something soon.
1 · Reply
handmedown1
handmedown1 Jan. 23 at 8:18 PM
$CRSP how did the ceo.manage to get such a nice 60 price and then it backs off. That smells weird.
0 · Reply
Ntlacrsp
Ntlacrsp Jan. 23 at 8:14 PM
$CRSP any reason this pos is down 10 % today other than not generating any revenue or any pipe line products are anywhere close to getting FDA approval?? I guess I just answered my own question!!
1 · Reply
randallthedane
randallthedane Jan. 23 at 7:55 PM
$CRSP this works. Bought Wednesday at 53 sold yesterday at 60. Just bought back in today at 55.60
0 · Reply
Boots8
Boots8 Jan. 23 at 7:42 PM
$CRSP glad you'll booked your return ticket yesterday
0 · Reply
BullYa
BullYa Jan. 23 at 7:03 PM
$CRSP Bank of America its $89 price target, WHILE maintaining a Buy rating, implying about a 46.7% upside from the recent share price
0 · Reply
JasonCO
JasonCO Jan. 23 at 6:53 PM
$CRSP going for the round-tripper
0 · Reply
Gen21NASDAQmicropro
Gen21NASDAQmicropro Jan. 23 at 6:52 PM
$CRSP 98% of the CEO's pay is from stock according to his last pkg of $31MM in stock and option comp. This was a pre-planned 10b5-1 sale from last August so use this selling pressure as a BUYING opportunity!
2 · Reply